4/6/2020 1:07:52 AM
ObsEva Nominates Fabien De Ladonchamps As Interim CFO
1/15/2020 1:08:02 AM
ObsEva To Provide Corporate Plans For 2020
1/13/2020 1:06:09 AM
ObsEva And Yuyuan Announce Sublicense Agreement To Develop Nolasiban In The People's Republic Of China
12/9/2019 1:10:52 AM
ObsEva Announces Positive Results From Uterine Fibroids Phase 3 Study Of Linzagolix (PRIMROSE 2)
10/9/2019 1:04:17 AM
ObsEva SA To Present New Clinical Data On Nolasiban And Linzagolix At The 75th Annual ASRM Meeting In Philadelphia
8/7/2019 1:14:23 AM
Obseva Posts Q2 Loss Per Share Of $0.80; Announces $75 Mln Credit Facility With Oxford Finance
7/18/2019 7:52:24 AM
Wedbush Reiterates ObsEva SA (OBSV) At Outperform With $38 Price Target
7/8/2019 1:15:14 AM
ObsEva SA Announces Completion Of Patient Recruitment In PRIMROSE 1 Phase 3 Clinical Trial Of Linzagolix
7/1/2019 1:56:01 AM
ObsEva Appoints Elizabeth Garner As Chief Medical Officer And Member Of Executive Committee, Effective July 15
6/19/2019 5:02:19 PM
Wedbush Reiterates ObsEva SA (OBSV) At Outperform With $38 Price Target
6/19/2019 1:04:32 AM
ObsEva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting
6/4/2019 1:01:47 AM
ObsEva SA Announces Completion Of Patient Recruitment In IMPLANT 4 Phase 3 Clinical Trial Of Nolasiban
11/28/2018 1:04:43 AM
ObsEva Begins Phase 3 IMPLANT 4 Trial Of Nolasiban In Europe, Canada And Russia For Improving IVF Outcomes
11/8/2018 1:46:09 AM
ObsEva Q3 Net Loss $18.6 Mln Or $0.42/Shr Vs $17.0 Mln Or $0.59/Shr Last Year
10/5/2018 1:02:28 AM
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results Of Nolasiban In IVF